Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study
Zhi‐Cheng Jin, Bin‐Yan Zhong, Jian-Jia Chen, et al.
European Radiology (2023) Vol. 33, Iss. 12, pp. 8669-8681
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
Zhi‐Cheng Jin, Jian-Jia Chen, Xiaoli Zhu, et al.
EClinicalMedicine (2024) Vol. 72, pp. 102622-102622
Open Access | Times Cited: 44
Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study
Xukun Wu, Lanfang Yang, Yufeng Chen, et al.
EClinicalMedicine (2023) Vol. 67, pp. 102367-102367
Open Access | Times Cited: 22
Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives
Jian‐Jian Chen, Zhi‐Cheng Jin, Bin‐Yan Zhong, et al.
United European Gastroenterology Journal (2024) Vol. 12, Iss. 2, pp. 226-239
Open Access | Times Cited: 5
Immunotherapy improved the efficacy of TACE or TACE plus MTTs in HCC patients: A meta-analysis
Yusheng Guo, Zhenliang Pan, Xuefeng Kan, et al.
International Immunopharmacology (2025) Vol. 147, pp. 114006-114006
Closed Access
Ultrasound and CT-guided implantation of iodine-125 seeds combined with transarterial chemoembolization for recurrent hepatocellular carcinoma at complex sites after hepatectomy
Y WANG, Jie Feng
Brachytherapy (2025)
Closed Access
Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
Hongjie Cai, Song Chen, Shuang‐Yan Tang, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 3
Open Access
Combination locoregional and systemic therapies in hepatocellular carcinoma
Bin‐Yan Zhong, Wenzhe Fan, Justin J. Guan, et al.
˜The œLancet. Gastroenterology & hepatology (2025)
Closed Access
Targeting Glycolytic Enzymes with 3-Bromopyruvic Acid to Enhance the Efficacy of Interventional Embolization in Hepatocellular Carcinoma
Min Wang, Xiaoning Wu, Xu Cheng, et al.
Current Medical Science (2025)
Closed Access
Long-Term Outcomes of Transarterial Chemoembolization plus Ablation versus Surgical Resection in Patients with Large BCLC Stage A/B HCC
Yingwen Hou, Tian-Qi Zhang, Li Ma, et al.
Academic Radiology (2025)
Open Access
Combined TACE with Targeted and Immunotherapy versus TACE Alone Improves DFS in HCC with MVI: A Multicenter Propensity Score Matching Study
Xiaokun Chen, Xiangan Wu, Peng Wei, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 561-577
Open Access
New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma
Hanyuan Liu, Chunmei Wang, Ruiqiang Wang, et al.
Chinese Journal of Cancer Research (2024) Vol. 36, Iss. 2, pp. 167-194
Open Access | Times Cited: 4
Application of multi-omics in hepatocellular carcinoma: new prospects for classification and precise diagnosis and treatment
Jiaxue He, Xintong Hu, Liguo Chen, et al.
Hepatoma Research (2025)
Open Access
PD1+ Treg cell remodeling promotes immune homeostasis within peripheral blood and tumor microenvironment after microparticles-transarterial chemoembolization in hepatocellular carcinoma
Zhizhong Ren, Yaqin Wang, Dandan Jiang, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 3
Open Access
Increment of Skeletal Muscle Mass Predicts Survival Benefit for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors
Wen Chen, Hai‐Tao Yan, Jin-Xing Zhang, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 415-426
Open Access
Case Report: Successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barré syndrome
Ye Lin, Wenbo Yue, Hao Shi, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM
Jiahao Li, Lei Xian, Xinsen Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis
Jingyi Li, Bowen Yang, Zan Teng, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Comparing Safety and Efficacy of TACE + Apatinib in Combination with a PD-1 Inhibitor versus a Non-triple Therapy for Treating Advanced Primary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
Di Pan, Haonan Liu, Pengfei Qu, et al.
Journal of Gastrointestinal and Liver Diseases (2024) Vol. 33, Iss. 1, pp. 85-93
Open Access | Times Cited: 2
Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis
Jingwen Feng, Yi Zhao, Lin Zhai, et al.
Medicine (2024) Vol. 103, Iss. 18, pp. e38037-e38037
Open Access | Times Cited: 2
Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study
Xiumei Jiang, Pan Wang, Ke Su, et al.
Annals of Hepatology (2024), pp. 101578-101578
Open Access | Times Cited: 2
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213)
Zhi‐Cheng Jin, Jiawei Zhou, Jian‐Jian Chen, et al.
Journal of Cachexia Sarcopenia and Muscle (2024) Vol. 15, Iss. 6, pp. 2705-2716
Open Access | Times Cited: 2
Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma
Juan Wu, Jia Zeng, Huiwen Wang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape
Shamar Young, Jack Hannallah, Dan Goldberg, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11434-11434
Open Access | Times Cited: 5
Prognosis Prediction of CRAFITY Score in HCC Undergoing TACE Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapy
Ze-Xin Hu, Xiao-Yang Xu, Ze Wang, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 2073-2082
Open Access | Times Cited: 5
Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study
Hao Li, Jiacheng Wang, Guokun Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top